research Drug Repurposing Patent Applications July–September 2025
New drug uses show promise but need more research.
Search
for
Sort by
Research
660-690 / 1000+ results research Alpha-blockers/finasteride: no benefit in ED
research Neoadjuvant therapy with Disitamab vedotin in treating muscle-invasive bladder cancer: A case report
Disitamab vedotin and gemcitabine effectively treated bladder cancer without major side effects.
research Management of acne vulgaris with hormonal therapies in adult female patients
Hormonal therapies, like flutamide and cyproterone acetate, are safe and effective for treating adult women's acne, especially those with hormone imbalance or resistant acne.
research FDA vetoes labelling proposals for finasteride, dutasteride
research Use of trilostane for the treatment of pituitary‐dependent hyperadrenocorticism in a cat
Trilostane helped a cat with a hormone issue but the cat later died from a kidney infection.
research Drug repurposing—a promising approach for patients with angina but non-obstructive coronary artery disease (ANOCA)
Using existing drugs for new purposes could be a cost-effective way to treat chest pain and non-clogged heart arteries, with some drugs for lung blood pressure showing promise but needing more testing.
research Novel 5α-reductase inhibitors unlinked to depression-like phenotypes in rat model of BPH
research The Utility of Monitoring Potassium in Transgender, Gender Diverse, and Nonbinary Individuals on Spironolactone
Young transgender, gender diverse, and nonbinary people on spironolactone have a low risk of high potassium, so frequent monitoring may not be needed.
research Effects of adenosine triphosphate on vandetanib induced skin damage in rats
ATP helps prevent skin damage from vandetanib by reducing stress.
research Progesterone and its Metabolites: Anticonvulsant and Behavioral Studies
Progesterone and its metabolites can prevent seizures without major side effects.
research Post-marketing safety profile of cladribine in multiple sclerosis: a disproportionality analysis based on the FDA adverse event reporting system
Cladribine has known risks and potential new safety concerns, requiring careful monitoring.
research The combined use of intravenous and oral calcium for the treatment of vitamin D dependent rickets type II (VDDRII)
Intravenous and oral calcium effectively treated vitamin D dependent rickets type II, improving growth and bone health.
research Optimizing clinical monitoring and management guidelines for capivasertib in HR-positive/HER2-negative advanced breast cancer: expert opinion
Capivasertib improves survival in certain breast cancer cases but requires careful management of side effects.
research Transdermal Delivery of Valproate–Choline Ionic Liquid Induces Hair Regrowth
A new treatment using valproic acid helps regrow hair safely.
research Using Sodium Valproate in Children <2 Years of Age: Study in a District Hospital, Dinajpur, Bangladesh
Sodium valproate caused vomiting in 20% of children under 2 years old, with other side effects like hair loss and loss of appetite also noted.
research Beneficial Effects of Vitamin B12 and Aureomycin in Rats Given Large Doses of Cortisone.
Vitamin B12 and aureomycin reduce the negative effects of high doses of cortisone in rats.
research Determination of vinflunine in Beagle dog′s plasma by LC-MS and study of its pharmacokinetics
The method accurately measures vinflunine in dog plasma.
research Long-Term Efficacy and Complete Scalp Hair Regrowth in Patients With Alopecia Areata Receiving Ritlecitinib 50 mg QD Up to 3 Years in the ALLEGRO Clinical Trial Program
Ritlecitinib 50 mg effectively promotes and sustains hair regrowth in alopecia areata patients.
research Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies
Ritlecitinib is effective and safe for long-term use in treating severe alopecia areata in people aged 12 and older.
research Adverse event reporting of four anti-Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: a real-world study based on the FDA adverse event reporting system
These migraine prevention drugs can cause side effects like constipation, hair loss, injection site reactions, fatigue, and sometimes unexpected issues like Raynaud's phenomenon and weight gain.
research Pharmacokinetics of 2 Novel Formulations of Modified-Release Oral Testosterone Alone and With Finasteride in Normal Men With Experimental Hypogonadism
New oral testosterone formulations show potential for safer, effective hormone replacement in men with low testosterone.
research Miscellaneous Steroids
The document concludes that scientists created various steroids with different properties, including a more effective semi-synthetic vitamin D.
research Role of liposomal anthracyclines in the treatment of multiple myeloma
Liposomal anthracyclines are effective and safer for treating multiple myeloma, especially in elderly patients.
research Bicalutamide: A review
Bicalutamide may help treat female pattern hair loss.
research Warfarin: almost 60 years old and still causing problems
Warfarin is effective but risky, requiring careful monitoring to prevent bleeding.
research Testosterone therapy in women: Myths and misconceptions
Testosterone therapy is beneficial for women's health and does not cause masculinization or liver damage, and it protects the heart and breasts.
research Safety and efficacy of transdermal testosterone for treatment of hypoactive sexual desire disorder
Transdermal testosterone can improve sexual desire in postmenopausal women but lacks long-term safety data and is not FDA-approved for this use.
research Isoallopregnanolone reduces tic‐like behaviours in the D1 CT ‐7 mouse model of Tourette syndrome
Isoallopregnanolone may be a safe and effective treatment for reducing tics in a mouse model of Tourette syndrome.
![The Synthesis of (−)-4-Methyl-8-Chloro-Trans-1,2,3,4,4a,5,6,10b-Octahydrobenzo-[f]-Quinolin-3-One-[3-14C] (LY300502-14C) via a Circuitous Route](/images/assets/73bab8dc-bdf0-45e3-8ef7-73d0d4b93cb1/small/21074.jpg)
research The synthesis of (−)-4-methyl-8-chloro-trans-1,2,3,4,4a,5,6,10b-octahydrobenzo-[f]-quinolin-3-one-[3-14C] (LY300502-14C]) via a circuitous route
Scientists made a carbon-14 labeled version of a drug with a 48% yield and over 99% purity.